Related Experiment Video
Updated: Mar 13, 2026
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
The pathophysiologic profile of congestive heart failure
Robert H Haber1, M D Thierry LeJemtel1, Edmund H Sonnenblick1
1Albert Einstein College of Medicine, 1300 Morris Park Avenue, 10461, Bronx, New York, USA.
Insights
Congestive heart failure (CHF) involves cardiac hypertrophy and pressure increases due to excessive workload or myocardial loss. Early interventions may prevent degeneration, but cellular changes leading to mortality require further identification.
Area of Science:
- Cardiology
- Pathophysiology
Background:
- Congestive heart failure (CHF) arises from excessive cardiac workload or myocardial loss, leading to hypertrophy, increased pressure, and reduced functional reserve.
- Ischemic cardiomyopathy accounts for nearly 60% of heart failure cases, characterized by biventricular dilatation and left ventricular hypertrophy.
- Idiopathic dilated cardiomyopathy affects 30-40% of patients, presenting with tissue loss, reactive hypertrophy, and fibrosis.
Purpose of the Study:
- To explore the mechanisms driving congestive heart failure progression.
- To investigate the potential of early interventions in mitigating adverse cardiac remodeling.
- To identify cellular changes critical for understanding and reducing heart failure mortality.
Main Methods:
- Review of existing literature on congestive heart failure pathophysiology.
- Analysis of etiological factors including ischemic and idiopathic dilated cardiomyopathies.
- Examination of the impact of myocardial loss and workload on cardiac structure and function.
Main Results:
- Cardiac hypertrophy and increased pressure are common consequences of both excessive workload and myocardial loss in CHF.
- Early afterload reduction shows promise in alleviating hypertrophic stimuli and preventing cardiac degeneration.
- Cellular ultrastructural changes in idiopathic dilated cardiomyopathy require further investigation.
Conclusions:
- Understanding the progression of CHF, particularly the cellular mechanisms of degeneration, is crucial for reducing mortality.
- Further research into pharmacologic interventions and cellular changes is needed for effective CHF management.
Abstract:
Congestive heart failure (CHF) evolves either from an excessive workload or in response to loss of myocardium, both of which cause cardiac hypertrophy, increased cardiac pressure, and loss of functional reserve. Nearly 60% of patients in heart failure present with ischemic cardiomyopathy, which in its chronic form exhibits biventricular dilatation, elevated left ventricular mass, and extensive large-vessel atherosclerosis. The hypertrophy is proportional to the loss of myocardium, although animal studies suggest this varies with the infarct size. However, recent studies indicate that early afterload reduction may relieve the hypertrophic stimulus and prevent degeneration. Some 30% to 40% of patients in heart failure present with an idiopathic dilated cardiomyopathy, with a patchy but diffuse loss of tissue on microscopy, reactive hypertrophy in the surviving cells, and interstitial fibrosis and replacement scarring. The ultrastructural changes still await clarification. The role of pharmacologic intervention still remains unclear. However, any reduction in mortality will necessitate the identification of those cellular changes that inevitably lead to secondary degeneration of the remaining viable myocardium.
Related Concept Videos
01:17Pathophysiology of Heart Failure
01:29Heart Failure II: Pathophysiology
01:27Heart Failure I: Introduction
01:26Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:26Heart Failure III: Clinical Manifestations